Skip to main content
Nanologica logo

Nanologica — Investor Relations & Filings

Ticker · NICA ISIN · SE0005454873 LEI · 54930017L41C7P87LP22 ST Manufacturing
Open in API
Filings indexed 181 across all filing types
Latest filing 2024-02-02 Earnings Release
Country SE Sweden
Listing ST NICA

About Nanologica

https://nanologica.com/

Nanologica is a life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers. The company specializes in nanoporous silica particles for preparative chromatography, a critical step in drug production. Its core product, NLAB Saga®, is a spherical, porous silica media engineered for the large-scale purification of peptide drugs, such as insulin and GLP-1 analogues used to treat diabetes and obesity. The product's high mechanical and chemical stability provides effective purification and a long lifetime, which increases productivity and reduces costs for pharmaceutical manufacturers. Nanologica's mission is to lower the manufacturing costs of these drugs, thereby increasing patient access to life-saving treatments. The company is also developing a broader portfolio of purification media.

Recent filings

Filing Released Lang Actions
Earnings Release 2023
Earnings Release Classification · 99% confidence The document is titled "BOKSLUTSKOMMUNIKÉ 2023 NANOLOGICA AB (PUBL)" which translates to "YEAR-END REPORT COMMUNICATION 2023 NANOLOGICA AB (PUBL)". It contains a detailed financial summary for the fourth quarter and the full year (2023 vs 2022), including key figures like net sales, operating result, net result, and earnings per share. It also includes a CEO's statement and a section on significant events. This structure is characteristic of a periodic financial report covering a full fiscal year, which aligns with the definition of an Annual Report (10-K) or, given the Swedish context and the nature of the content (which often precedes or substitutes a formal 10-K filing in non-US contexts, or is a comprehensive year-end summary), it strongly suggests a comprehensive annual financial disclosure. Since the definitions provided include 'Annual Report (Code: 10-K)' and the content is a full year-end financial communication, 10-K is the closest fit for a comprehensive annual report, even if the specific filing might be a local equivalent like an Årsredovisning (which often maps to 10-K in classification systems). The length (98,337 chars) confirms it is a substantial report, not just a brief announcement (RPA/RNS). Q4 2023
2024-02-02 Swedish
Audit Report / Information 2023
Audit Report / Information Classification · 98% confidence The document is explicitly titled "YEAR-END REPORT 2023" and contains a detailed "FINANCIAL SUMMARY" with key figures for the fourth quarter and the full year (Jan - Dec 2023), including Net sales, Operating loss, Loss after tax, and Earnings per share. It also includes a CEO comment and extensive business review covering the entire fiscal year. This structure and content strongly indicate a comprehensive annual financial report. Although the text mentions a planned Extraordinary General Meeting regarding a rights issue, the primary document type is the annual financial disclosure, which corresponds to the Annual Report (10-K) definition, even if the company is not explicitly filing a US SEC Form 10-K, as this category serves as the primary annual financial disclosure document in this classification scheme. FY 2023
2024-02-02 English
KALLELSE TILL EXTRA BOLAGSSTÄMMA I NANOLOGICA AB (PUBL)
AGM Information Classification · 99% confidence The document is titled "KALLELSE TILL EXTRA BOLAGSSTÄMMA I NANOLOGICA AB (PUBL)" which translates to "NOTICE OF EXTRAORDINARY GENERAL MEETING IN NANOLOGICA AB (PUBL)". It details the date, time, location, registration requirements, agenda items (including proposals for a rights issue approval, capital reduction, and granting an authorization for future share issues), and voting majorities required for decisions. This content is characteristic of a formal notice calling shareholders to a meeting to vote on corporate actions, which aligns perfectly with the definition of AGM Information (AGM-R), specifically for an Extraordinary General Meeting (EGM), which falls under the broader category of AGM-R materials.
2024-01-30 Swedish
NOTICE OF EXTRAORDINARY GENERAL MEETING IN NANOLOGICA AB (PUBL)
AGM Information Classification · 100% confidence The document is explicitly titled "NOTICE OF EXTRAORDINARY GENERAL MEETING IN NANOLOGICA AB (PUBL)". It details the date, time, location, shareholder registration requirements, proxy instructions, and the proposed agenda for an extraordinary general meeting (EGM). The agenda items (6, 7, 8) concern resolutions related to share issuance, capital reduction, and board authorization, which are typical matters voted upon at a general meeting. This content directly corresponds to the purpose of an AGM/EGM notice, which falls under the 'AGM Information' category.
2024-01-30 English
Nanologica Resolves on a Fully Guaranteed Rights Issue of approximately SEK 54.2 m, an Over-allotment Issue of up to approximately SEK 10 m and to Change the Publication Date of the Year-end 2023 Repo
Capital/Financing Update Classification · 98% confidence The document is a press release announcing a fully guaranteed Rights Issue of approximately SEK 54.2 million, an Over-allotment Issue, and a change in the publication date for the year-end 2023 report. The core subject matter is a significant fundraising and capital structure change involving the issuance of new shares to existing shareholders with preferential rights. This directly aligns with the definition of 'Capital/Financing Update' (CAP). Although it mentions changing the date of the year-end report, the primary focus and bulk of the text detail the financing terms, commitments, and shareholder approval required for the share issue.
2024-01-30 English
Nanologica beslutar om en fullt garanterad företrädesemission om cirka 54,2 MSEK, en övertilldelningsemission om upp till cirka 10 MSEK och att tidigarelägga publiceringen av bokslutskommunikén 2023
Capital/Financing Update Classification · 98% confidence The document is a press release written in Swedish detailing a proposed rights issue ('Företrädesemission') and an over-allotment option ('Övertilldelningsemission') totaling approximately 54.2 MSEK plus up to 10 MSEK. It discusses capital structure changes, shareholder approval requirements (Extra bolagsstämma), subscription commitments, and the use of proceeds for production equipment and working capital. This content directly aligns with the definition of 'Capital/Financing Update' (CAP), which covers company fundraising and capital structure changes. It is not an Annual Report (10-K), an Earnings Release (ER), or a simple announcement of a report (RPA/RNS), as it contains the substantive details of the financing event itself.
2024-01-30 Swedish

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.